MSCI (formerly KLD and GMI)
MSCI ESG Ratings and MSCI Indexes into their security selection and portfolio construction processes, stress testing, and risk and performance attribution analysis.
在GMI 交易的理由
聯繫原因(最多選擇3個)
- 所屬國家: 英國
- 成立時間: 2009年
- 最低入金: 2000美金 在GMI 交易的理由
- 平臺軟體: GMI MT4、GMI 在GMI 交易的理由 ClearPro
- 交易手數: Standard賬戶 0.01標手、Plus賬戶 0.01標手、Pro賬戶 0.01標手、ECN賬戶 1000合約
- 經營模式: 100% STP/ECN
- 入金方式: 銀聯
- 出金優惠: 在GMI 交易的理由 在GMI 交易的理由 安全便捷、本地貨幣到帳
- 服務器區時: GMT+2
- 暫無IB政策信息,請聯繫店鋪客服獲取
GMI
信用檔案
口碑評分: 4.在GMI 交易的理由 6分 4條口碑 643513 人關注
- 官方網址: https://www.gmimarkets.com
- 郵箱: [email protected]
- 中文網址:
- 電話: 400 606 3399
投資者保障信息
英國FCA
監管信息更多>
- 監管狀態: 監管中
- 監管號碼: 677530
- 業務權限: 機構外匯等
- 牌照類型: STP直通式牌照
- 生效時間: 2015-11-23
- 到期時間: --
- GMI_FCA监管查询截图
[查看證明文件]
在同花顺上面怎么查看10分钟的股票涨速排名?
本站部分文章基于互联网的整理,我们会把真正“有用/优质”的文章整理提供给浏览者。如果文章所有者并不想本站转载其文章,请邮件: ,收到邮件后我们即刻回复,并即刻处理。
A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer
Recruitment Status : Terminated (After demonstrating the on target effect of GMI-1359 via pharmacodynamic markers (CXCR4 在GMI 交易的理由 and E-selectin), Sponsor terminated the trial due to COVID-related slow enrollment.)
- Study Details
Go to
This 在GMI 交易的理由 trial is being conducted to investigate the safety, tolerability, pharmacokinetics (the effect the body has on the drug), and pharmacodynamics (the effect the drug has on the body) of GMI-1359 when given with standard-of-care treatment to subjects with HR+ metastatic breast cancer.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HR+ Metastatic Breast Cancer Breast Cancer Breast Cancer Metastatic | Drug: GMI-1359 | Phase 1 |
Go to
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 4 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 1b, Single and 在GMI 交易的理由 Multiple Dose, Open-Label Trial of Intravenous GMI-1359 in HR+ Metastatic 在GMI 交易的理由 Breast Cancer Subjects |
Actual Study Start Date : | November 21, 2019 |
Actual Primary Completion Date : | August 25, 2021 |
Actual Study Completion Date : | August 25, 2021 |
Resource links provided by the National Library of Medicine